メモブログ

Intracerebral Hemorrhage (ICH) is an extremely serious condition, accounting for approximately 20–25% of all strokes. It is not only life-threatening but also carries a high risk of leaving severe residual disabilities. This disease is predominantly caused by hypertension, and the symptoms that appear vary significantly depending on the site of the bleeding (e.g., putamen, thalamus, cerebellum).

The treatment for Intracerebral Hemorrhage (ICH) evolves rapidly depending on the time elapsed since onset and the location of the bleeding. The first 6 hours, in particular, constitute the "Hyperacute Phase," where treatments aimed at halting the expansion of the hemorrhage and controlling intracranial pressure have the greatest impact on prognosis.

Intracerebral Hemorrhage (ICH) is an extremely dangerous condition where a patient's state can change drastically and become life-threatening within just a few hours of onset. The first 6 hours are particularly critical—the "battleground for treatment"—as bleeding is likely to expand, and the risk of loss of consciousness or respiratory arrest due to brainstem compression is highest.

Intracerebral hemorrhage (ICH) is a severe condition where a blood vessel within the brain ruptures, causing bleeding that destroys or compresses brain cells. The location of the bleeding significantly affects its cause, presenting symptoms, severity, and treatment plan. ICH is primarily classified into five types, ranging from Putaminal Hemorrhage, which is most frequent in Japan, to Pontine Hemorrhage, which has the highest fatality rate.

Cerebral hemorrhage (intracerebral hemorrhage) and cerebral infarction (ischemic stroke), often collectively referred to as "stroke," have fundamentally different mechanisms of onset, fatality rates, treatments, and keys to prevention. While cerebral infarction is overwhelmingly more common, occurring 2 to 3 times more frequently annually and showing significant treatment advancements, the threat of cerebral hemorrhage remains significant, with a high fatality rate of 30–50%.